ASPR said in a statement the expansion will focus on the development of innovative products to combat the potentially deadly health effects of chemical, biological, radiation and nuclear threats, emerging infectious diseases and antimicrobial resistant infections.
ASPR’s Biomedical Advanced Research and Development Authority will manage a portfolio of products with Johnson & Johnson. Through the agreement, BARDA will have joint oversight, share the cost of developing the portfolio, help to determine which products to develop and collaborate on decisions about which products enter or leave each partnership’s portfolio.
Under the terms of the agreement, BARDA will provide more than $28 million over two years and up to $200 million over six years. The Johnson & Johnson Family of Companies also will provide a significant portion of the funding needed to bring products in the portfolio to the market.
The first project funded will be an early development compound that can be used for acute radiation syndrome and certain potential chemical threats. The compound has demonstrated enhanced survival and beneficial effects on blood cells that can be injured by high doses of radiation.
According to HHS, the portfolio will focus on countermeasures for radiation and nuclear threats. The agreement also allows BARDA and Johnson & Johnson to collaborate on the development of a portfolio of medical products.
The products will address areas such as bleeding caused by trauma, injuries caused by chemical and emerging threats and bacterial infections. The partnership builds on a 2017 portfolio agreement with Janssen Research & Development LLC, a subsidiary of Johnson & Johnson focused on pandemic influenza antiviral drugs and vaccines.